|
|
Prepublished online as a Blood First Edition Paper on September 5, 2002; DOI 10.1182/blood-2002-06-1736.
Previous Article | Table of Contents | Next Article 
Blood, 15 January 2003, Vol. 101, No. 2, pp. 602-610
IMMUNOBIOLOGY
Glycosylation-dependent inhibition of cutaneous
lymphocyte-associated antigen expression: implications in modulating
lymphocyte migration to skin
Charles J. Dimitroff,
Ralph J. Bernacki, and
Robert Sackstein
From the Department of Dermatology and the Harvard Skin
Disease Research Center at Brigham and Women's Hospital, Boston,
MA; Grace Cancer Drug Center, Department of Pharmacology and
Therapeutics, Roswell Park Cancer Institute, Buffalo, NY; and
Department of Medicine, Massachusetts General Hospital, Boston, MA.
Constitutive E-selectin expression on dermal microvascular
endothelial cells plays a critical role in mediating rolling adhesive interactions of human skin-homing T cells and in pathologic
accumulation of lymphocytes in skin. The major E-selectin ligand on
human skin-homing T cells is cutaneous lymphocyte-associated antigen
(CLA), a specialized glycoform of P-selectin glycoprotein ligand-1
(PSGL-1) defined by monoclonal antibody HECA-452. Since HECA-452
reactivity, and not PSGL-1 polypeptide itself, confers the specificity
of human T cells to enter dermal tissue, inhibition of HECA-452
expression is a potential strategy for modulating lymphocyte migration
to skin. In this study, we examined the efficacy of several
well-characterized metabolic inhibitors of glycosylation and of a novel
fluorinated analog of N-acetylglucosamine
(2-acetamido-1,3,6-tri-O-acetyl-4-deoxy-4-fluoro-D-glucopyranose [4-F-GlcNAc]) to alter HECA-452 expression on human
CLA+ T cells and prevent cell tethering and rolling on
selectins under shear stress. At concentrations that did not affect
PSGL-1 expression, we found that swainsonine (inhibitor of complex-type
N-glycan synthesis) had no effect on HECA-452 expression
or selectin ligand activity, whereas
benzyl-O-N-acetylgalactosamide (BAG; inhibitor of O-glycan biosynthesis) ablated HECA-452 expression on
PSGL-1 and significantly lowered selectin ligand activity. We found
that 4-F-GlcNAc (putative inhibitor of poly-N-acetyllactosamine
biosynthesis) was more potent than BAG at lowering HECA-452 expression
and selectin binding. In addition, we show that 4-F-GlcNAc was directly
incorporated into native CLA expressed on T cells, indicating direct
inhibition on poly-N-acetyllactosamine elongation and
selectin-binding determinants on PSGL-1 O-glycans. These
observations establish a potential treatment approach for targeting
pathologic lymphocyte trafficking to skin and indicate that 4-F-GlcNAc
may be a promising agent for treatment of dermal tropism associated
with malignancies and inflammatory disorders.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. C. Kerr, C. B. Fieger, K. R. Snapp, and S. D. Rosen
Endoglycan, a Member of the CD34 Family of Sialomucins, Is a Ligand for the Vascular Selectins
J. Immunol.,
July 15, 2008;
181(2):
1480 - 1490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Gainers, L. Descheny, S. R. Barthel, L. Liu, M.-A. Wurbel, and C. J. Dimitroff
Skin-Homing Receptors on Effector Leukocytes Are Differentially Sensitive to Glyco-Metabolic Antagonism in Allergic Contact Dermatitis
J. Immunol.,
December 15, 2007;
179(12):
8509 - 8518.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. V. Cabrera, M. Amano, J. Mitoma, J. Chan, J. Said, M. Fukuda, and L. G. Baum
Haploinsufficiency of C2GnT-I glycosyltransferase renders T lymphoma cells resistant to cell death
Blood,
October 1, 2006;
108(7):
2399 - 2406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ohmori, F. Fukui, M. Kiso, T. Imai, O. Yoshie, H. Hasegawa, K. Matsushima, and R. Kannagi
Identification of cutaneous lymphocyte-associated antigen as sialyl 6-sulfo Lewis X, a selectin ligand expressed on a subset of skin-homing helper memory T cells
Blood,
April 15, 2006;
107(8):
3197 - 3204.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Dimitroff, L. Descheny, N. Trujillo, R. Kim, V. Nguyen, W. Huang, K. J. Pienta, J. L. Kutok, and M. A. Rubin
Identification of Leukocyte E-Selectin Ligands, P-Selectin Glycoprotein Ligand-1 and E-Selectin Ligand-1, on Human Metastatic Prostate Tumor Cells
Cancer Res.,
July 1, 2005;
65(13):
5750 - 5760.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-J. Chang, K.-F. Tai, S. Roffler, and L.-H. Hwang
The Immunization Site of Cytokine-Secreting Tumor Cell Vaccines Influences the Trafficking of Tumor-Specific T Lymphocytes and Antitumor Efficacy against Regional Tumors
J. Immunol.,
November 15, 2004;
173(10):
6025 - 6032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. K. Myers, J. Myllyharju, M. Nokelainen, D. D. Brand, M. A. Cremer, J. M. Stuart, M. Bodo, K. I. Kivirikko, and A. H. Kang
Relevance of Posttranslational Modifications for the Arthritogenicity of Type II Collagen
J. Immunol.,
March 1, 2004;
172(5):
2970 - 2975.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|